# TCD Capital

> TCD Capital is a VC fund in Uccle backing Biotechnology and Health Care. See 18 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Uccle, Belgium
- Total investments: 18
- Last investment: Oct 2024
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/theclubdeal-sa/
- X (Twitter): https://twitter.com/tcd_com
- Website: https://theclubdeal.com/

TCD Capital is a VC fund in Uccle focused on Biotechnology and Health Care. TheClubDeal is an investment holding and fund manager co-investing into SME’s and real estate projects. It provides facilitation of governance between non-executive shareholders and entrepreneurs. Its governance structure, including its charter of avoidance of conflict of interests, is therefore paramount to the adequate management of the Company.At TheClubDeal, we connect Investors and Entrepreneurs around promising investment opportunities. For each of these, we will invest ourselves and co-invest with a selected number of investors. We add value by processing strong applied governance principles, when selecting and managing our investments, and by gathering the necessary skills to successfully grow the businesses and real-estate projects we co-invest in. TheClubDeal is launching their second fund, a 50M € PRIVAK/PRICAF in H1 2021 with the mandate to invest in Belgian scale-ups in three sectors: Smart Living, Tech and Life Sciences.

## Contacts

5 contacts available for TCD Capital. Shizune tracks 7 team members at TCD Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/theclubdeal?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $2.1M–$7.7M |
| Series B | $13M–$18M |
| Venture - Series Unknown | $5.5M–$6.5M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 22% |
| Health Care | 3 | 17% |
| Medical Device | 2 | 11% |
| Clinical Trials | 2 | 11% |
| Information Technology | 2 | 11% |

31 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 9 | 50% |
| Series B | 2 | 11% |
| Venture - Series Unknown | 2 | 11% |
| Seed | 1 | 6% |
| Series C | 1 | 6% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 10 | 56% |
| France | 4 | 22% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jean-Louis Dubrule | Executive partner and Board Member | 0 | https://shizune.co/investors/profile/jean-louis-dubrule |
| Jean-Marc Legrand | Founder & Managing Director | 0 | https://shizune.co/investors/profile/jean-marc-legrand-cd0b |
| Xavier de Villepin | Business & Investment Manager | 0 | https://shizune.co/investors/profile/xavier-de-villepin |
| Edouard de Becker Remy | Investment Analyst | 0 | https://shizune.co/investors/profile/edouard-de-becker-remy |
| Frederic Convent | Senior Investment Manager | 0 | https://shizune.co/investors/profile/frederic-convent |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Vaxinano | Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder. | $6.5M | Venture - Series Unknown | Oct 29, 2024 |  |
| Clouds of care | CLOUDS OF CARE aids HealthTech firms from algorithm validation to medical device software, focusing on regulatory compliance. | $5.5M | Venture - Series Unknown | Sep 04, 2024 |  |
| Inpulse | Inpulse is an automated supply management platform for restaurateurs. | $7.7M | Series A | Apr 19, 2023 |  |
| Univercells | Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. | $43.3M | Series D | Oct 17, 2022 |  |
| FLYX.cloud | FLYX.cloud enables retail chains to maximise value from each customer in multiple industries (such as Food, Grocery and Fuel) and in an omni-channel sales model. | $2.1M | Series A | Jun 01, 2022 |  |
| Smartflats | Smartflats constructs and distributes a range of flats for its clients.The company provides its users with an online platform to make bookings for their stay. It enables them to make food orders and obtain transfer services. Furthermore, it provides wireless internet, TVs, coffee makers, irons, and hairdryers.Smartflats was founded in 2012 byTarik Hennen and Alexandre Szmaj. | $4.9M | Series A | Oct 01, 2021 |  |
| Sortlist | Because finding the right partner in the fast-growing digital environment is a hard task, we have built an online multi-criteria searching tool strongly linked to professional networks and peer-to-peer recommendations. Sortlist helps marketing managers find their partners in minutes and let them focus on building communication and marketingsuccess.Start your search now on www.sortlist.com | $13M | Series B | Sep 15, 2021 |  |
| Univercells | Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. | $24.5M | Series C | Dec 17, 2020 |  |
| Univercells | Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. |  | Series C | Aug 31, 2020 |  |
| Yust Group | Co-Living, Smart Living |  | Seed | Apr 30, 2019 |  |

10 of 18 investments shown.

## Co-investors
- [S.R.I.W.](https://shizune.co/investors/profile/s-r-i-w) — VC Fund, 3 deals together
- [Adjuvant Capital](https://shizune.co/investors/profile/adjuvant-capital) — VC Fund, 2 deals together
- [Innovation Fund](https://shizune.co/investors/profile/innovation-fund-2) — VC Fund, 2 deals together
- [Korea Investment Partners](https://shizune.co/investors/profile/korea-investment-partners) — VC Fund, 2 deals together
- [SFPI-FPIM](https://shizune.co/investors/profile/sfpi-fpim) — VC Fund, 2 deals together
- [3d investors](https://shizune.co/investors/profile/3d-investors) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [All VC Funds in Belgium](https://shizune.co/investors/vc-funds-belgium)
- [All Investors in Belgium](https://shizune.co/investors/investors-belgium)
- [Software VC Funds in Belgium](https://shizune.co/investors/software-vc-funds-belgium)
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)
- [Health Care VC Funds in Belgium](https://shizune.co/investors/health-care-vc-funds-belgium)
- [SaaS VC Funds in Belgium](https://shizune.co/investors/saas-vc-funds-belgium)

## FAQ

### What does TCD Capital invest in?

TCD Capital invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is TCD Capital's check size?

TCD Capital typically joins rounds of $2.1M–$7.7M at Series A, $13M–$18M at Series B and $5.5M–$6.5M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds TCD Capital participates in.

### How do I contact TCD Capital?

Public channels for TCD Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at TCD Capital?

The team at TCD Capital includes Jean-Louis Dubrule (Executive partner and Board Member), Jean-Marc Legrand (Founder & Managing Director) and Xavier de Villepin (Business & Investment Manager), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co